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Hormone replacement therapy has been a conventional treatment for postmenopausal 
symptoms in women. However, it has potential risks of breast and endometrial cancers. The 
aim of this study was to evaluate the oestrogenicity of a plant-based compound, mimosine, in 
MCF-7 cells by in silico model. Cell viability and proliferation, ERα-SRC1 coactivator activity 
and expression of specific ERα-dependent marker TFF1 and PGR genes were evaluated. 
Binding modes of 17β-oestradiol and mimosine at the ERα ligand binding domain were 
compared using docking and molecular dynamics simulation experiments followed by binding 
interaction free energy calculation with molecular mechanics/Poisson-Boltzmann surface area. 
Mimosine showed increased cellular viability (64,450 cells/ml) at 0.1 μM with significant cell 
proliferation (120.5%) compared to 17β-oestradiol (135.2%). ER antagonist tamoxifen 
significantly reduced proliferative activity mediated by mimosine (49.9%). Mimosine at 1 μM 
showed the highest ERα binding activity through increased SRC1 recruitment at 186.9%. It 
expressed TFF1 (11.1-fold at 0.1 μM) and PGR (13.9-fold at 0.01 μM) genes. ERα-mimosine 
binding energy was -49.9 kJ/mol, and it interacted with Thr347, Gly521 and His524 of ERα-
LBD. The results suggested that mimosine has oestrogenic activity.  
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